Rhapsido Becomes First FDA-Approved Treatment for Hives Triggered by Scratching, but Fewer Than a Third Fully Cleared
Novartis' Rhapsido (remibrutinib) received FDA approval for symptomatic dermographism (SD) in adults unresponsive to antihistamines. Trial data showed 29.3% of patients had complete symptom relief after 12 weeks, compared to 14.0% on placebo. The drug, priced at $4,521 for a 30-day supply, carries bleeding risks and insurance coverage varies. Novartis is also studying Rhapsido for other conditions.
How this was made
The 30-second read
Why it matters
The approval creates a new market for Novartis, potentially adding revenue while raising questions about insurance coverage and safety.
Market read
First‑in‑class FDA approval likely to lift Novartis stock and influence biotech sector sentiment.
What to watch
Reimbursement challenges and exclusion of Medicare/Medicaid could constrain sales volume.
Background
The article reports the first FDA‑approved treatment for symptomatic dermographism, a condition affecting ~3% of adults, and details trial results, safety profile, and pricing.
Ticker impact
Novartis received FDA approval for Rhapsido (remibrutinib) to treat symptomatic dermographism, a new indication for the drug.
potential upside as investors price in the new revenue stream from the approved indication
The FDA decision is a primary disclosure; the drug targets a 3.2% prevalence condition and may generate multi‑year sales, prompting a positive market reaction.
Market effects
Strengthens the biotech/dermatology segment and may boost other BTK‑inhibitor developers.
U.S. biotech stocks could see modest gains as the approval highlights pipeline potential.
Adds to global FDA approval momentum, potentially influencing foreign markets with similar regulatory pathways.
Counterpoint
Pricing at $4,521 per month and bleeding risk may limit adoption, tempering upside.
Key entities
- CompanyNovartis
Pharmaceutical company that received FDA approval for Rhapsido.
- DrugRhapsido (remibrutinib)
BTK inhibitor approved for symptomatic dermographism.
